US Stock Insider Trading | NewAmsterdam Pharma disclosed two insider trading transactions on March 12

On March 12, 2026, NewAmsterdam Pharma (NAMS) disclosed two instances of insider trading by company insiders. On March 11, 2026, Director LANGE LOUIS G sold 44.2k shares.

[Recent Insider Trading]

[Company Profile]

NewAmsterdam Pharma Company N.V. was established under Dutch law as a private limited liability company under the name NewAmsterdam Pharma B.V. on October 17, 2019. In October 2021, NewAmsterdam Pharma was renamed NewAmsterdam Pharma Holding B.V. They are a clinical-stage biopharmaceutical company developing oral non-statin drugs for patients at high risk for cardiovascular diseases (CVD) with persistently elevated low-density lipoprotein cholesterol (LDL-C, or LDL) for whom existing therapies are not sufficiently effective or are well tolerated. As an add-on therapy to statin drugs, there is a significant unmet need for an effective, cost-effective, and convenient low-density lipoprotein lowering therapy. Statin drugs are currently the standard of care for high-risk CVD patients with high cholesterol. Their primary candidate product, obicetrapib, is a next-generation, oral, low-dose cholesterol ester transfer protein (CETP) inhibitor. It is currently being evaluated in four Phase 3 and Phase 2b clinical trials, as both a single therapy and in combination therapy with ezetimibe, to reduce LDL-C and help prevent major adverse cardiovascular events (“MACE”).